DiaMedica Therapeutics (NASDAQ:DMAC) Downgraded by Wall Street Zen to Strong Sell

Key Points

• DiaMedica Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”, even though the stock still carries a broader consensus rating of “Moderate Buy” from analysts.
• The company recently reported Q earnings of -$0.19 per share, missing estimates of -$0.17, and analysts now expect -0.84 EPS for the current fiscal year.
• Shares opened at $6.32, below both the 50-day moving average of $6.88 and the 200-day moving average of $7.56, while institutional ownership remains relatively limited at 10.12%.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued on Saturday.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research note on Monday, April 20th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, DiaMedica Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $12.33.

DiaMedica Therapeutics Price Performance

Shares of DiaMedica Therapeutics stock opened at $6.32 on Friday. The stock has a market cap of $340.52 million, a price-to-earnings ratio of -8.90 and a beta of 0.99. The firm's 50-day moving average is $6.88 and its 200 day moving average is $7.56. DiaMedica Therapeutics has a 1 year low of $3.47 and a 1 year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). On average, equities analysts expect that DiaMedica Therapeutics will post -0.84 EPS for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Cooperman Leon G boosted its stake in DiaMedica Therapeutics by 98.2% during the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company's stock valued at $22,463,000 after purchasing an additional 1,619,761 shares during the last quarter. Millennium Management LLC purchased a new stake in DiaMedica Therapeutics during the 3rd quarter valued at $8,157,000. Paragon Associates & Paragon Associates II Joint Venture boosted its stake in DiaMedica Therapeutics by 34.6% during the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company's stock valued at $6,011,000 after purchasing an additional 225,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in DiaMedica Therapeutics by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 764,255 shares of the company's stock valued at $6,085,000 after purchasing an additional 52,437 shares during the last quarter. Finally, State Street Corp boosted its stake in DiaMedica Therapeutics by 31.7% during the 4th quarter. State Street Corp now owns 627,771 shares of the company's stock valued at $4,997,000 after purchasing an additional 151,188 shares during the last quarter. 10.12% of the stock is currently owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc NASDAQ: DMAC is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company's lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica's research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.